Latest news with #SageTherapeutics
Int'l Business Times
2 hours ago
- Business
- Int'l Business Times
Markets Rebound As Conflict Containment Hopes Ease Investor Jitters
U.S. stocks rallied Monday as investor confidence returned, buoyed by optimism that the escalating hostilities between Israel and Iran may remain contained. The S&P 500 rose 0.9% to close at 6,033.11, bolstered by a standout performance from Estée Lauder, which surged 10.78%. The Nasdaq climbed 1.52% to 19,701.21, and the Dow Jones added 0.8%, closing at 42,515.09, supported in part by gains across the banking sector. The rebound in sentiment extended across global markets. South Korea's Kospi advanced 1.8%, and Japan's Nikkei 225 climbed 1.3%, marking some of the day's strongest performances. Chinese markets also ticked higher after new data showed a rise in consumer spending in May, despite headwinds in industrial growth and investment. Stocks gained 0.7% in Hong Kong and 0.3% in Shanghai. Energy markets painted a contrasting picture. Despite continuing military exchanges between Israel and Iran, oil prices slipped after spiking late last week. Brent crude, the global benchmark, dropped 2% to $72.78 per barrel, while West Texas Intermediate fell 2.4% to $71.23. Analysts pointed to easing concerns about disruptions to global oil flows, especially with no direct impact on the Strait of Hormuz, a critical shipping lane. Hopes for diplomacy surfaced as Iran's foreign minister hinted at potential U.S. engagement following reports of high-level communication between Washington and Israeli leadership. Nonetheless, the conflict showed no signs of abating, with missile attacks ongoing. An Israeli airstrike reportedly disrupted Iranian state media temporarily, while Iran's recent missile barrage into Israel claimed 11 lives. Back on Wall Street, positive investor sentiment was also reflected in corporate news. Sage Therapeutics soared 35.4% after agreeing to a potential $795 million buyout by Supernus Pharmaceuticals. U.S. Steel rose 5.1% following a U.S. executive order enabling Japanese firm Nippon Steel to invest, potentially giving the government oversight over its operations. Those gains helped counter losses in the defense sector. Shares of Lockheed Martin and Northrop Grumman both declined nearly 4%, pulling back from Friday's surge driven by conflict-related demand expectations. Gold also reversed course, dropping 1.4% to $3,403 per ounce after a brief flight to safety the previous trading day. Investor attention is now shifting to the Federal Reserve's upcoming policy meeting. While markets broadly expect interest rates to remain unchanged, new forecasts from Fed officials could sway sentiment. Analysts at Bank of America suggest only one rate cut might be penciled in for the year—fewer than the two anticipated by investors. Inflation remains within the Fed's 2% target, though uncertainty around U.S. trade policy, including tariffs imposed by President Trump, continues to cast a shadow. With the G7 summit underway and additional economic data such as May retail sales on the horizon, markets appear cautiously optimistic—though far from complacent.
Yahoo
13 hours ago
- Business
- Yahoo
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio
Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base. Strengthens Supernus' leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform. Expected to be significantly accretive in 2026 with potential cost synergies of up to $200 million on an annual basis. Upfront cash payment of $8.50 per share, plus one non-tradable contingent value right (CVR) payable upon achieving certain specific milestones collectively worth up to $3.50 per share in cash, for an aggregate of up to approximately $795 million or $12.00 per share. Supernus to host conference call and webcast today at 8:30 a.m. ET. ROCKVILLE, Md. and CAMBRIDGE, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) and Sage Therapeutics, Inc. (Nasdaq: SAGE), today announced a definitive agreement for Supernus to acquire Sage through a tender offer for $8.50 per share in cash (or an aggregate of approximately $561 million), payable at closing, plus one non-tradable contingent value right (CVR) collectively worth up to $3.50 per share in cash (or an aggregate of approximately $234 million), for total consideration of $12.00 per share in cash (or an aggregate of up to approximately $795 million). The CVR is payable upon achieving certain net sales and commercial milestones. The transaction is expected to close in the third quarter of 2025. The transaction will provide Supernus with an innovative marketed product: ZURZUVAE® (zuranolone) capsules CIV, the first and only U.S. Food and Drug Administration (FDA)-approved oral medicine indicated for the treatment of adults with postpartum depression. Through a collaboration agreement with Biogen, Inc., Supernus will report collaboration revenue that is 50% of total net revenue Biogen records for ZURZUVAE in the U.S. 'This acquisition represents a major step in bolstering our future growth. It augments our growth profile by adding a significant fourth growth product to our portfolio and further diversifies our sources of future growth. ZURZUVAE aligns with our focus of acquiring novel value-enhancing and clinically-differentiated medicines to treat CNS conditions,' said Jack Khattar, President and CEO of Supernus Pharmaceuticals. 'We have a proven track record of strong commercial execution, and we look forward to building on ZURZUVAE's U.S. growth momentum and collaboration with Biogen, so that more women with postpartum depression can benefit from this novel treatment.' 'Since our founding, Sage Therapeutics has been committed to pioneering new solutions in brain health, one of the most complex and underserved areas of medicine,' said Barry Greene, Chief Executive Officer, Sage Therapeutics. 'We are proud of what we've accomplished, including successfully developing and commercializing ZURZUVAE, the first and only oral treatment for women with postpartum depression. This transaction follows a comprehensive strategic review by our Board of Directors, and I am confident this deal maximizes value for shareholders. I want to express my deepest gratitude to the Sage team for their unwavering commitment to brain health and improving the lives of patients. We look forward to our next chapter with Supernus.' Strategic and Financial Benefits Strengthens psychiatry portfolio with ZURZUVAE® (zuranolone) capsules CIV, the first and only FDA-approved oral medicine indicated for the treatment of postpartum depression in adults. Diversifies and increases revenue base and cash flow. Collaboration revenue from net sales of ZURZUVAE (representing 50% of the net revenue recorded by Biogen) was $36.1 million and $13.8 million for the full year 2024 and for the first quarter of 2025, respectively. Combined with its three other growth products (Qelbree®, ONAPGOTM, and GOCOVRI®), Supernus believes it is poised for significant future growth. Augments Supernus central nervous system (CNS) discovery platforms and expertise. Strong fit with existing Supernus infrastructure is expected to result in cost synergies of up to $200 million on an annual basis. The acquisition is expected to be significantly accretive in 2026. Terms and Financing Under the terms of the agreement, Supernus will commence a tender offer to acquire all outstanding shares of Sage Therapeutics, Inc. for a purchase price of $8.50 per share in cash (or an aggregate of approximately $561 million) payable at closing plus one non-tradable CVR. All cash consideration will be funded through existing balance sheet cash. The CVR entitles Sage stockholders to receive up to an additional $3.50 per share payable upon ZURZUVAE achieving certain sales and commercial milestones within certain specified periods (subject to the terms and conditions contained in a Contingent Value Rights Agreement detailing the terms of the CVR). These milestones include (1) $1.00 per share payable if in any calendar year between closing and end of 2027, annual net sales of ZURZUVAE allocable to Supernus reach $250 million or more in the U.S., (2) $1.00 per share payable if in any calendar year between closing and end of 2028, annual net sales of ZURZUVAE allocable to Supernus reach $300 million or more in the U.S., (3) $1.00 per share payable if in any calendar year between closing and end of 2030, annual net sales of ZURZUVAE allocable to Supernus reach $375 million or more in the U.S., and (4) $0.50 per share at first commercial sale in Japan to a third-party customer after regulatory approval for ZURZUVAE for the treatment of major depressive disorder (MDD) in Japan by June 30, 2026. Approvals and Timing of Close The transaction, which has been approved by the boards of directors of both companies, is expected to close in the third quarter of 2025, subject to customary closing conditions, including receipt of required regulatory approvals and the tender of a majority of the outstanding shares of Sage's common stock. Following the successful closing of the tender offer, Supernus will acquire any shares of Sage that are not tendered in the tender offer through a second-step merger at the same consideration as paid in the tender offer. Full Year Financial Guidance Supernus will provide revised full year 2025 financial guidance after the closing of the transaction, which is expected in the third quarter of 2025. Advisors Moelis & Company LLC is acting as the exclusive financial advisor to Supernus. Goldman Sachs & Co. LLC is acting as the exclusive financial advisor to Sage. Saul Ewing LLP is serving as legal counsel to Supernus. Kirkland & Ellis LLP is serving as legal counsel to Sage. Conference Call and Webcast Information A conference call and a live webcast will be hosted today, June 16, 2025, at 8:30 a.m. ET, to discuss the transaction. A live webcast will be available in the Events & Presentations section of the Supernus Investor Relations website Participants may also pre-register any time before the call here. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time. Following the live call, a replay will be available on the Supernus Investor Relations website The webcast will be available on the Supernus website for 60 days following the live call. About Supernus Pharmaceuticals, Inc. Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel CNS product candidates including new potential treatments for epilepsy, depression, and other CNS disorders. For more information, please visit About Sage Therapeutics Sage Therapeutics (Nasdaq: SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments indicated for postpartum depression and is advancing a pipeline to target unmet needs in brain health. Sage was founded in 2010 and is headquartered in Cambridge, Mass. Find out more at or engage with us on Facebook, LinkedIn, Instagram, and X. For more information about ZURZUVAE, please visit Additional Information About the Tender Offer and Where to Find It The tender offer for the outstanding common stock of Sage Therapeutics, Inc. ('Sage') has not been commenced. This filing does not constitute a recommendation, an offer to purchase or a solicitation of an offer to sell Sage securities. At the time the tender offer is commenced, Supernus Pharmaceuticals, Inc. ('Supernus') will file a Tender Offer Statement on Schedule TO (including an Offer to Purchase) with the Securities and Exchange Commission (the 'SEC') and thereafter, Sage will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC, in each case, with respect to the tender offer. The solicitation and offer by Supernus to purchase shares of Sage common stock will only be made pursuant to such Offer to Purchase and related materials. Once filed, investors and security holders are urged to read these materials (including the Offer to Purchase, a related Letter of Transmittal and certain other tender offer documents, as each may be amended or supplemented from time to time) carefully since they will contain important information that Sage investors and security holders should consider before making any decision regarding tendering their common stock, including the terms and conditions of the tender offer. The Tender Offer Statement, Offer to Purchase, Solicitation/Recommendation Statement and related materials will be filed with the SEC, and Sage investors and security holders may obtain a free copy of these materials (when available) and other documents filed by Supernus, Purchaser and Sage with the SEC at the website maintained by the SEC at In addition, the Tender Offer Statement and other documents that Supernus and Purchaser file with the SEC will be made available to all investors and security holders of Sage free of charge from the information agent for the tender offer. Investors may also obtain, at no charge, the documents filed with or furnished to the SEC by (i) Supernus under the 'Investor Relations' section of Supernus's website at and (ii) Sage under the 'Investors & Media' section of Sage's website at Supernus Forward-Looking Statements This press release includes forward-looking statements. These statements do not convey historical information but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the risk that the proposed acquisition of Sage by Supernus may not be completed; the possibility that competing offers or acquisition proposals for Sage will be made; the delay or failure of the tender offer conditions to be satisfied (or waived), including insufficient shares of Sage common stock being tendered in the tender offer; the failure (or delay) to receive the required regulatory approvals of the proposed acquisition; the possibility that prior to the completion of the transactions contemplated by the acquisition agreement, Supernus' or the Sage's business may experience significant disruptions due to transaction related uncertainty; the effects of disruption from the transactions of Sage's business and the fact that the announcement and pendency of the transactions may make it more difficult to establish or maintain relationships with employees, manufactures, suppliers, vendors, business partners and distribution channels to patients; the occurrence of any event, change or other circumstance that could give rise to the termination of the acquisition agreement; the risk that stockholder litigation in connection with the proposed transaction may result in significant costs of defense, indemnification and liability; the failure of the closing conditions set forth in the acquisition agreement to be satisfied or waived; Supernus' ability to sustain and increase its profitability; Supernus' ability to raise sufficient capital to fully implement its corporate strategy; the implementation of Supernus' corporate strategy; Supernus' future financial performance and projected expenditures; Supernus' ability to increase the number of prescriptions written for each of its products and products acquired through the acquisition of Sage; Supernus' ability to increase its net revenue from its products and products acquired through the acquisition of Sage; Supernus' ability to commercialize its products including Qelbree; Supernus' ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; Supernus' product research and development activities, including the timing and progress of Supernus' clinical trials, and projected expenditures; Supernus' ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize Supernus' product candidates; Supernus' ability to protect its intellectual property and operate its business without infringing upon the intellectual property rights of others; Supernus' expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of Supernus' product candidates; the accuracy of Supernus' estimates of the size and characteristics of the markets that may be addressed by its product candidates; Supernus' ability to increase its manufacturing capabilities for its products and product candidates; Supernus' projected markets and growth in markets; Supernus' product formulations and patient needs and potential funding sources; Supernus' staffing needs; and other risk factors set forth from time to time in Supernus' filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. Supernus undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events. Sage Forward Looking Statements This press release contains forward-looking statements related to Sage, Supernus, the tender offer for outstanding shares of Sage common stock (the 'Offer'), the merger of Saphire, Inc., a Delaware corporation and a wholly owned subsidiary of Supernus with and into Sage, with Sage surviving as a wholly owned subsidiary of Supernus (the 'Merger'), the Agreement and Plan of Merger, dated June 13, 2025, by and among Supernus, Purchaser, and Sage (the 'Merger Agreement') and the other transactions contemplated by the Merger Agreement (collectively, the 'Transactions') that involve substantial risks and uncertainties. Forward-looking statements include any statements containing the words 'anticipate,' 'believe,' 'contemplate,' 'estimate,' 'expect,' 'intend', 'goal,' 'may', 'might,' 'plan,' 'predict,' 'project,' 'seek,' 'opportunity,' 'target,' 'potential,' 'will,' 'would,' 'could,' 'should,' 'continue' and similar expressions. In this press release, Sage's forward-looking statements include statements about the parties' ability to satisfy the conditions to the consummation of the Offer and the other conditions to the consummation of the Transactions; statements about the expected timetable for completing the Transactions; Sage's plans, objectives, expectations and intentions; the financial condition, results of operations and business of Sage and Supernus; Sage's ability to commercialize current and future product candidates (including further commercialization of ZURZUVAE); and the anticipated timing of the closing of the Transactions. Forward-looking statements are subject to certain risks, uncertainties or other factors that are difficult to predict, and could cause actual events or results to differ materially from those indicated in any such statements due to a number of risks and uncertainties. Those risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include, among other things: uncertainties as to the timing of the Offer and the Merger; uncertainties as to how many of Sage's stockholders will tender their Shares in the Offer; risks related to non-achievement of the CVR milestones and that holders of the CVRs will not receive any payments in respect of those CVRs; the possibility that competing offers will be made; the possibility that various closing conditions for the Transactions may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the Transactions; the effects of the Transactions on relationships with employees, other business partners or governmental entities; the difficulty of predicting the timing or outcome of U.S. Food and Drug Administration approvals or actions, if any; the impact of competitive products and pricing; that Supernus may not realize the potential benefits of the Transactions; other business effects, including the effects of industry, economic or political conditions outside of the companies' control; transaction costs; actual or contingent liabilities; Sage's launch and commercialization efforts in the U.S. with respect to ZURZUVAE for the treatment of women with PPD may not be successful; ZURZUVAE may not achieve the clinical benefit, clinical use or market acceptance for the treatment of PPD Sage or Supernus expects or they may encounter reimbursement, market access, process-related or other issues, including competition in the market, that impact the success of their commercialization efforts; ZURZUVAE may never become the standard of care for women with PPD; and other risks listed under the heading 'Risk Factors' in the Company's periodic reports filed with the U.S. Securities and Exchange Commission, including current reports on Form 8-K, quarterly reports on Form 10-Q, annual reports on Form 10-K, as well as the Schedule 14D-9 to be filed by Sage and the Schedule TO and related tender offer documents to be filed by Supernus and Purchaser. You should not place undue reliance on these statements. All forward-looking statements are based on information currently available to Sage and Supernus, and Sage and Supernus disclaim any obligation to update the information contained in this press release as new information becomes available. SELECT IMPORTANT SAFETY INFORMATION FOR ZURZUVAE ZURZUVAE (zuranolone) CIV, is a neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive modulator indicated for the treatment of postpartum depression in adults. This does not include all the information needed to use ZURZUVAE safely and effectively. See full prescribing information for ZURZUVAE. ZURZUVAE may cause serious side effects, including decreased awareness and alertness, which can affect your ability to drive safely or safely do other dangerous activities. Do not drive, operate machinery, or do other dangerous activities until at least 12 hours after taking each dose. You may not be able to tell on your own if you can drive safely or tell how much ZURZUVAE is affecting you. ZURZUVAE may cause central nervous system (CNS) depressant effects including sleepiness, drowsiness, slow thinking, dizziness, confusion, and trouble walking. Taking alcohol, other medicines that cause CNS depressant effects such as benzodiazepines, or opioids while taking ZURZUVAE can make these symptoms worse and may also cause trouble breathing. ZURZUVAE is a federally controlled substance schedule IV because it contains zuranolone, which can be abused or lead to dependence. Tell your healthcare provider right away if you become pregnant or plan to become pregnant during treatment with ZURZUVAE. You should use effective birth control (contraception) during treatment with ZURZUVAE and for 1 week after the final dose. ZURZUVAE and other antidepressant medicines may increase the risk of suicidal thoughts and actions in people 24 years of age and younger. ZURZUVAE is not for use in children. The most common side effects of ZURZUVAE include sleepiness or drowsiness, dizziness, common cold, diarrhea, feeling tired, weak, or having no energy, and urinary tract infection. Supernus Pharmaceuticals ContactsJack A. Khattar, President and CEOTim Dec, Senior Vice President and CFOSupernus Pharmaceuticals, Inc.(301) 838-2591 Investors:Peter VozzoICR Healthcare(443) 213-0505Email: Sage Therapeutics ContactsInvestor ContactAshley Media ContactFrancesca in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Reuters
13 hours ago
- Business
- Reuters
Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal
June 16 (Reuters) - Drugmaker Supernus Pharmaceuticals (SUPN.O), opens new tab said on Monday it will acquire Sage Therapeutics (SAGE.O), opens new tab, which makes treatments for neurological conditions, in a deal worth up to $795 million. Supernus has offered $8.50 in cash for each of Sage's share and up to $3.50 per share in cash if certain milestones are achieved. Shares of Sage Therapeutics were halted in premarket trading.
Yahoo
19-05-2025
- Health
- Yahoo
Neuromodulation: rewiring healthcare?
Once niche, the field of neuromodulation is now accelerating toward real-world breakthroughs for conditions such as tinnitus, substance use disorder, Parkinson's disease and epilepsy. According to a report by GlobalData, the global neurological devices market will reach a valuation of $20.9bn by 2033, up from $12.5bn in 2023. At Biomed Israel 2025: the 23rd National Life Science & Technology Week, taking place in Tel Aviv between 20 and 22 May, Serendipity Impact VC co-founder and managing partner Avi Yaron will give a keynote during a session titled 'Rewiring the Brain: Breakthroughs in Neurotech and Neuromodulation'. Moderated by Barry Greene, CEO of Sage Therapeutics; and Iris Grossman, chief therapeutics officer at Eleven Therapeutics, the session will also feature a keynote from Tanya Fischer, chief medical officer at Tenvie Therapeutics and presentations from companies such as NeuroSense Therapeutics and BrainValue NeuroTech. Diagnosed with a brain tumour at the age of 26, Yaron embarked on a self-advocacy quest to bring into being the neurotech required to help save his life – a story he shared in a TEDx talk in 2015. Yaron's investment fund's rationale is to invest in early technologies to transform mental and neuro health, with his personal journey having led him to the belief that in keeping people healthy, the future of medicine will be driven by personalised, predictive, preventative systems in which neuromodulation devices have a critical role to play. Medical Device Network sat down with Yaron to gain more insight into the value in neuromodulation and what the future holds for treating a range of neurological conditions. Avi Yaron (AY): Let's say that I have a headache. While I can take a pill to no longer 'feel' the headache, the headache is still there. The pharmacological element just shuts down the neurotransmitter so I won't feel it, but the pain is still there; and once I stop taking the pill, the headache and the pain being felt, may return. Unlike pharma, advanced neuromodulation technologies have the potential, either to completely cure or at least allow a person to reach a state of remission. Many neurodegenerative conditions, from depression and anxiety to Parkinson's and Alzheimer's disease, take over the person. Their life is no longer their life, but the life of their disease. By using neuromodulation to address their conditions, they are given back their lives and don't face the potential of being reliant on drugs for the rest of their lives as a means of eliminating their symptoms. I'm not against drugs. For certain conditions that we still don't fully understand, like schizophrenia, pharmaceuticals allow individuals to lead a normal life. Rather, I'm for people having the potential to take advantage of the new developments gradually moving towards becoming a reality, as an alternative to pharmaceuticals. As with most things, an evolution is assisted by many small revolutions. Neuromodulation has been an option for at least 30 years, but it is nowadays becoming a lot more advanced. If you look at Responsive Neurostimulation (RNS), for instance, it is possible to effectively eliminate epileptic seizures before they occur. With Parkinson's, neuromodulation approaches can delay its onset. In my view, this is just the beginning of the evolution being seen in this field. I am genuinely convinced that neuromodulation represents the next frontier of medicine. AY: Today, more people are developing more diseases at a younger age. I believe that it's always good to have a plethora of potential treatments, so a physician can decide on the most appropriate approach to an individual's needs. On the acute side, it may be best to use pharmacology, but on the chronic side, where pharma typically fails, technology can be used instead. In turn, the rise of other technologies such as AI allows for the ability to more easily crunch big data and bring greater personalisation to patients with neurological conditions. It makes no sense that males and females, youngsters and elders, or those with dark or light skin, receive the same treatment approach to their neurological condition. There is no one-size-fits-all. With neuro technology such as closed-loop neuromodulation, a technique that monitors brain activity or physiological signals and dynamically adjusts brain stimulation parameters in real-time, more personalised treatment modalities can be determined. And with the ability of such technologies to gather more information, in sync with AI, this not only empowers the patient, but it can also help direct them to the right treatment and the right physician. AY: One of the companies that Serendipity has invested in enables minimally invasive approaches to treat forms of epilepsy that were considered untreatable before. This example provides an integrative use of various technologies that serve medicine and serve mankind to make treatment better, more accurate, more personalised, less invasive and less traumatic. In turn, with what will hopefully be a wider availability of technologies like this in future, I believe that, knowing these non-invasive approaches are available, that people who were afraid of treatment before would now go and get diagnosed and therefore receive treatment earlier. In time, developments of this sort will hopefully not only reduce costs to healthcare systems but also help reduce individual suffering. AY: Startups here are leaner and often take less time and money to reach a certain result compared to those in other regions. I think that another huge advantage of Israeli startups is that they have to go global from day one. In my view, this outward-looking perspective is allowing the Israeli ecosystem to flourish in the field of neuromodulation. "Neuromodulation: rewiring healthcare?" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-04-2025
- Business
- Yahoo
Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025
CAMBRIDGE, Mass., April 15, 2025--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE) today announced that it will host a live webcast on Tuesday, April 29, 2025, at 4:30 p.m. ET to review first quarter 2025 financial results and discuss recent business updates. The webcast can be accessed on the Investor page of Sage's website at A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. About Sage Therapeutics Sage Therapeutics (Nasdaq: SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. Sage was founded in 2010 and is headquartered in Cambridge, Mass. Find out more at or engage with us on Facebook, LinkedIn, Instagram, and X. View source version on Contacts Investor Contact Ashley Media Contact Francesca Sign in to access your portfolio
